Non Small Cell Lung Cancer Clinical Trials in Plantation, Florida

8 studies are recruiting for non small cell lung cancer in Plantation, Florida right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

   Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Clinical Study Site, Plantation, Florida

   Locations

   285 in total

   Run by

   Summit Therapeutics

   See if you can join NCT06767514 on ClinicalTrials.gov

2. Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

   This clinical trial is designed to assess the efficacy and safety of trastuzumab deruxtecan (T-DXd; Enhertu®) in combination with pembrolizumab versus platinum-based chemotherapy in combination with pembrolizumab in participants with no prior therapy for locally advanced unresectable or metastatic …

   Stage

   Phase 3

   Ages

   18 and older

   Site

   BRCR Global Plantation, Plantation, Florida

   Locations

   242 in total

   Run by

   Daiichi Sankyo

   See if you can join NCT06899126 on ClinicalTrials.gov

3. Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

   The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to docetaxel.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   BRCR Global, Plantation, Florida

   Locations

   153 in total

   Run by

   Revolution Medicines, Inc.

   See if you can join NCT06881784 on ClinicalTrials.gov

4. Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

   This is a Phase 3 Randomized, double-blind, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer. The primary endpoint is overall survival and progression free survival ass…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   BRCR Medical Center Inc, Plantation, Florida

   Locations

   260 in total

   Run by

   Summit Therapeutics

   See if you can join NCT05899608 on ClinicalTrials.gov

5. Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC

   The purpose of this study is to evaluate the efficacy of an investigational RAS(ON) inhibitor administered in combination with pembrolizumab and platinum-based chemotherapy doublet compared to placebo in combination with pembrolizumab and platinum-based chemotherapy doublet.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Florida Clinical Trials Group, LLC, Plantation, Florida

   Run by

   Revolution Medicines, Inc.

   See if you can join NCT07777822 on ClinicalTrials.gov

6. This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

   The purpose of the study is to compare how the new combination treatment (Sigvotatug Vedotin plus pembrolizumab) works compared to pembrolizumab alone in patients with non-small cell lung cancer (NSCLC) with high levels of PD-L1. This is a protein that acts as a kind of "brake" to keep the body's i…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   BRCR Global, Plantation, Florida

   Locations

   372 in total

   Run by

   Pfizer

   See if you can join NCT06758401 on ClinicalTrials.gov

7. Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer

   This Phase 2, open-label, randomized study in non-small-cell lung cancer (NSCLC) is designed to evaluate the efficacy and safety of an intravenously delivered oncolytic vaccinia virus, Olvi-Vec, followed by platinum-doublet chemotherapy + Physician's Choice of Immune Checkpoint Inhibitor (ICI) vs. …

   Stage

   Phase 2

   Ages

   18 and older

   Site

   BRCR Medical Center, Inc., Plantation, Florida

   Locations

   15 in total

   Run by

   Genelux Corporation

   See if you can join NCT06463665 on ClinicalTrials.gov

8. A Study of IBI363 in Subjects with Advanced Solid Malignancies

   This is a Phase 2, open-label, multicenter study designed to evaluate the efficacy, safety and tolerability of IBI363 (study drug) in subjects with advanced, refractory solid malignancies.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   BRCR Medical Center, Plantation, Florida

   Locations

   9 in total

   Run by

   Innovent Biologics (Suzhou) Co. Ltd.

   See if you can join NCT06281678 on ClinicalTrials.gov